BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ — Apexigen, Inc.
announced today that it has entered into a collaboration and
worldwide license agreement with Centocor Research &
Development, Inc. and its affiliates to utilize Apexigen’s
proprietary therapeutic antibody technologies to discover and
develop monoclonal antibody drugs. Apexigen will generate and
screen antibodies to several targets specified by Centocor R&D,
which will be responsible for development and commercialization of
all products resulting from the collaboration. While
financial details were not disclosed, Apexigen will receive an
upfront license fee, and is eligible to receive future milestone
and royalty payments if certain development and commercialization
milestones are achieved.
Apexigen’s antibody technologies produce a broad diversity of
antibodies with high specificity, high affinity, and unique
epitopes, and can successfully generate antibodies against
challenging antigens where competing technologies fail. This
enables the development of ‘best-in-class’ therapeutic antibodies.
“We’re excited about this collaboration and look forward to
working closely with Centocor R&D,” said Dr. Xiaodong Yang,
President & CEO of Apexigen. “Our goal is to become a
world leader in the development of best-in-class therapeutic
antibodies. To achieve this goal, we plan to collaborate with
partners while also developing our own product pipeline.”
Apexigen, Inc. is a biopharmaceutical company focused on the
discovery and development of best-in-class therapeutic antibodies.
Apexigen has exclusive rights to the proprietary antibody
technologies that were developed by Epitomics, Inc. for the
development and commercialization of human therapeutics. In
addition, Apexigen assumed development and commercialization
responsibility for a pipeline of therapeutic product programs
initiated by Epitomics.
Located in B